Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Novel neuroprotective drug improves recovery after acute ischemic stroke

7

Feb 2026

Novel neuroprotective drug improves recovery after acute ischemic stroke

Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting within 48 hours of stroke symptoms, had better recovery than patients who received a placebo, according to a preliminary late-breaking science presentation at the American Stroke Association's International Stroke Conference 2026.

High-dose motor therapy improves outcomes after perinatal stroke

7

Feb 2026

High-dose motor therapy improves outcomes after perinatal stroke

In infants and toddlers who had a stroke before birth or as a newborn (28 days or younger), a treatment that combined restricting the use of the stronger arm with intensive task-oriented physical therapy led to improved function and skill gained on the weak side compared to standard care, according to preliminary late-breaking science presented today at the American Stroke Association's International Stroke Conference 2026.

CRISPR gene-drive technology reverses antibiotic resistance in bacteria

7

Feb 2026

CRISPR gene-drive technology reverses antibiotic resistance in bacteria

Antibiotic resistance (AR) has steadily accelerated in recent years to become a global health crisis. As deadly bacteria evolve new ways to elude drug treatments for a variety of illnesses, a growing number of "superbugs" have emerged, ramping up estimates of more than 10 million worldwide deaths per year by 2050.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.